Hormone replacement therapy and ovarian cancer risk: A meta-analysis

Gynecologic Oncology

Volumn 108, Issue 3, 2008, Pages 641-651

  Zhou, Bo ^a   Sun, Qingmin ^a   Cong, Rihong ^a   Gu, Haijuan ^a   Tang, Naping ^a   Yang, Li ^a   Wang, Bin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Hormone replacement therapy; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN; GESTAGEN; HORMONE;

CANCER RISK; CASE CONTROL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

EID: 39249084221     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.12.003     Document Type: Review

References (79)

1. Greenlee R.T., Murray T., Bolden S., et al. Cancer statistics, 2000. CA Cancer J Clin 50 (2000) 7-33
2. Fathalla M.F. Incessant ovulation-a factor in ovarian neoplasia?. Lancet 2 (1971) 163
3. Cramer D.W., and Welch W.R. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71 (1983) 717-721
4. Whiteman D.C., Siskind V., Purdie D.M., et al. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 12 (2003) 42-46
5. Bosetti C., Negri E., Trichopoulos D., et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 102 (2002) 262-265
6. Siskind V., Green A., Bain C., et al. Breastfeeding, menopause, and epithelial ovarian cancer. Epidemiology 8 (1997) 188-191
7. Teede H.J. Hormone replacement therapy and the prevention of cardiovascular disease. Hum Reprod Update 8 (2002) 201-215
8. Wells G., Tugwell P., Shea B., et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23 (2002) 529-539
9. Anderson G.L., Judd H.L., Kaunitz A.M., et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 290 (2003) 1739-1748
10. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350 (1997) 1047-1059
11. Beral V., Bull D., and Reeves G. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 (2005) 1543-1551
12. Whittemore A.S., Hsrris R., and Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 136 (1992) 1212-1220
13. Garg P.P., Kerlikowske K., Subak L., et al. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92 (1998) 472-479
14. Coughlin S.S., Giustozzi A., Smith S.J., et al. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 53 (2000) 367-375
15. La Vecchia C. Estrogen-progestogen replacement therapy and ovarian cancer: an update. Eur J Cancer Prev 15 (2006) 490-492
16. Zheng H., Kavanagh J.J., Hu W., et al. Hormonal therapy in ovarian cancer. Int J Gynecol Cancer 17 (2007) 325-338
17. Hopkins M.L., Fung M.F., Le T., et al. Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecol Oncol 92 (2004) 827-832
18. Auranen A., Hietanen S., Salmi T., et al. Hormonal treatments and epithelial ovarian cancer risk. Int J Gynecol Cancer 15 (2005) 692-700
19. Loizzi V., Cormio G., Vicino M., et al. Hormone replacement therapy on ovarian and uterine cancer risk and cancer survivors: how shall we do no harm?. Int J Gynecol Cancer 15 (2005) 420-425
20. Higgins J.P., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
21. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
22. Rodriguez C., Patel A.V., Calle E.E., et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285 (2001) 1460-1465
23. Lacey Jr. J.V., Mink P.J., Lubin J.H., et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288 (2002) 334-341
24. Folsom A.R., Anderson J.P., and Ross J.A. Estrogen replacement therapy and ovarian cancer. Epidemiology 15 (2004) 100-104
25. Bakken K., Alsaker E., Eggen A.E., et al. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 112 (2004) 130-134
26. Kumle M., Weiderpass E., Braaten T., et al. Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Br J Cancer 90 (2004) 1386-1391
27. Lacey Jr. J.V., Brinton L.A., Leitzmann M.F., et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 98 (2006) 1397-1405
28. Danforth K.N., Tworoger S.S., Hecht J.L., et al. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer 96 (2007) 151-156
29. Rodriguez C., Calle E.E., Coates R.J., et al. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 141 (1995) 828-835
30. Hankinson S.E., Colditz G.A., Hunter D.J., et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76 (1995) 284-290
31. Mink P.J., Folsom A.R., Sellers T.A., et al. Physical activity, waist-to-hip ratio, and other risk factors for ovarian cancer: a follow-up study of older women. Epidemiology 7 (1996) 38-45
32. Hoover R., Gray Sr. L.A., and Fraumeni Jr. J.F. Stilboestrol (diethylstilbestrol) and the risk of ovarian cancer. Lancet 2 (1977) 533-534
33. Petitti D.B., Perlman J.A., and Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 70 (1987) 289-293
34. Adami H.O., Persson I., Hoover R., et al. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 44 (1989) 833-839
35. Hunt K., Vessey M., and McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol (1990) 971080-971086
36. Persson I., Yuen J., Bergkvist L., et al. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer 67 (1996) 327-332
37. Weiss N.S., Lyon J.L., Krishnamurthy S., et al. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 68 (1982) 95-98
38. Cramer D.W., Hutchison G.B., Welch W.R., et al. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 71 (1983) 711-716
39. Tzonou A., Day N.E., Trichopoulos D., et al. The epidemiology of ovarian cancer in Greece: a case-control study. Eur J Cancer Clin Oncol 20 (1984) 1045-1052
40. Hartge P., Hoover R., McGowan L., et al. Menopause and ovarian cancer. Am J Epidemiol 127 (1988) 990-998
41. Kaufman D.W., Kelly J.P., Welch W.R., et al. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 130 (1989) 1142-1151
42. Booth M., Beral V., and Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 60 (1989) 592-598
43. Polychronopoulou A., Tzonou A., Hsieh C.C., et al. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer 55 (1993) 402-407
44. Parazzini F., La Vecchia C., Negri E., et al. Estrogen replacement therapy and ovarian cancer risk. Int J Cancer 57 (1994) 135-136
45. Risch H.A. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 63 (1996) 254-257
46. Hempling R.E., Wong C., Piver M.S., et al. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol 89 (1997) 1012-1016
47. Salazar-Martinez E., Lazcano-Ponce E.C., Gonzalez Lira-Lira G., et al. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res 59 (1999) 3658-3662
48. Purdie D.M., Bain C.J., Siskind V., et al. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 81 (1999) 559-563
49. Tavani A., Ricci E., La Vecchia C., et al. Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer. Int J Epidemiol 29 (2000) 799-802
50. Chiaffarino F., Pelucchi C., Parazzini F., et al. Reproductive and hormonal factors and ovarian cancer. Ann Oncol 12 (2001) 337-341
51. Sit A.S., Modugno F., Weissfeld J.L., et al. Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 86 (2002) 118-123
52. Riman T., Dickman P.W., Nilsson S., et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94 (2002) 497-504
53. Pike M.C., Pearce C.L., Peters R., et al. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril 82 (2004) 186-195
54. Mills P.K., Riordan D.G., Cress R.D., et al. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev 29 (2005) 124-132
55. Moorman P.G., Schildkraut J.M., Calingaert B., et al. Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol 193 (2005) 76-82
56. La Vecchia C., Liberati A., and Franceschi S. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 69 (1982) 1207
57. Purdie D., Green A., Bain C., et al. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Int J Cancer 62 (1995) 678-684
58. Risch H.A., Marrett L.D., Jain M., et al. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 144 (1996) 363-372
59. Wynder E.L., Dodo H., and Barber H.R. Epidemiology of cancer of the ovary. Cancer 23 (1969) 352-370
60. Casagrande J.T., Louie E.W., Pike M.C., et al. "Incessant ovulation" and ovarian cancer. Lancet 2 (1979) 170-173
61. McGowan L., Parent L., Lednar W., et al. The woman at risk for developing ovarian cancer. Gynecol Oncol 7 (1979) 325-344
62. Annegers J.F., Strom H., Decker D.G., et al. Ovarian cancer: incidence and case-control study. Cancer 43 (1979) 723-729
63. Hildreth N.G., Kelsey J.L., LiVolsi V.A., et al. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 114 (1981) 398-405
64. Rosenberg L., Shapiro S., Slone D., et al. Epithelial ovarian cancer and combination oral contraceptives. JAMA 247 (1982) 3210-3212
65. Byers T., Marshall J., Graham S., et al. A case-control study of dietary and nondietary factors in ovarian cancer. J Natl Cancer Inst 71 (1983) 681-686
66. Smith E.M., Sowers M.F., and Burns T.L. Effects of smoking on the development of female reproductive cancers. J Natl Cancer Inst 73 (1984) 371-376
67. Nasca P.C., Greenwald P., Chorost S., et al. An epidemiologic case-control study of ovarian cancer and reproductive factors. Am J Epidemiol 119 (1984) 705-713
68. Whittemore A.S., Wu M.L., Paffenbarger Jr. R.S., et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol 128 (1988) 1228-1240
69. Beard C.M., Hartmann L.C., Atkinson E.J., et al. The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991. Ann Epidemiol 10 (2000) 14-23
70. McCann S.E., Freudenheim J.L., Marshall J.R., et al. Risk of human ovarian cancer is related to dietary intake of selected nutrients, phytochemicals and food groups. J Nutr 133 (2003) 1937-1942
71. Tung K.H., Goodman M.T., Wu A.H., et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 158 (2003) 629-638
72. Glud E., Kjaer S.K., Thomsen B.L., et al. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164 (2004) 2253-2259
73. Kotsopoulos J., Lubinski J., Neuhausen S.L., et al. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 100 (2006) 83-88
74. Bull D., Beral V., et al., Million Women Study Collaborators. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369 (2007) 1703-1710
75. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
76. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90 (1998) 1774-1786
77. Cramer D.W., and Welch W.R. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71 (1983) 717-721
78. O'Donnell A.J., Macleod K.G., Burns D.J., et al. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer 12 (2005) 851-866
79. Lau K.M., Mok S.C., and Ho S.M. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A 96 (1999) 5722-5727